Author

K. Ethirajulu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Research Focus:phylogenetics / evolution· 1 Organism:virus· 1

Frequent Co-Authors

H. HENTZE· 2 shared A. D. T. Barrett· 1 shared A. P. C. Lim· 1 shared B. H. Gan· 1 shared B. J. Hanson· 1 shared B. Young· 1 shared C. E. Z. Chan· 1 shared C.-T. K. Tseng· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

H. HENTZE

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacodynamic evaluation of AUM001/tinodasertib, an oral inhibitor of mitogen-activated protein kinase (MAPK)-interacting protein kinase 1, 2 (MNK1/2) in preclinical models and tissues from a Phase 1 clinical study

B. H. Gan, L. H. Lee, R. Takeda, M. Yasin, V. Teneggi, K. Ethirajulu, P. Yeo, D. Umrani, V. Pendharkar, D. W. T. Lim, G. Li, Q. Lu, Y. Cao, R. Nellore, S. Blanchard, , V. Novotny-Diermayr

This paper evaluates the pharmacodynamic effects of AUM001/tinodasertib in preclinical models and human tissues from a Phase 1 study, showing dose-dependent inhibition of eIF4E phosphorylation in tumors and PBMCs.

bioRxiv · Feb 23, 2024 · PreprintCancer Biology

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

C. E. Z. Chan, S. G. K. Seah, D. H. Chye, S. Massey, M. Torres, A. P. C. Lim, S. K. K. Wong, J. J. Y. Neo, P. S. Wong, J. H. Lim, G. S. L. Loh, D. L. Wang, J. D. Boyd-Kirkup, S. Guan, D. Thakkar, , B. J. Hanson

The paper identifies SC31, a potent SARS-CoV-2 neutralizing antibody, and shows that its Fc-mediated effector functions are critical for its therapeutic efficacy in vivo.

bioRxiv · Oct 26, 2020Microbiology